AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg intravenously (IV)
Number of subjects: 11
Study 10709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg subcutaneously (SC)
Number of subjects: 11
Study 10709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg IV
Number of subjects: 11
Study 10709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg SC
Number of subjects: 11
Study 10709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg IV and SC
Number of subjects: 11
Study 9350465 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive NSI Prevention Program including policy and procedure revisions
Number of subjects: 0
Study 1547881 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent interferon (IFN)-alpha at an initial dose of 4 x 10(6) U/m2 (arm A)
Number of subjects: 51
Study 1547881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IFN-alpha and low-dose IFN-gamma (arm B)
Number of subjects: 51
Study 3988412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min incremental cycle ergometer test
Number of subjects: 10
Study 3988412 — intervention group
Group type: COMPARATOR
Intervention: 3-min incremental cycle ergometer test
Number of subjects: 10
Study 3988412 — intervention group
Group type: COMPARATOR
Intervention: 5-min incremental cycle ergometer test
Number of subjects: 10
Study 3988412 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests (1, 3, and 5 min)
Number of subjects: 10
Study 3299440 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 1
Study 3299440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 1
Study 3299440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 30953874 — intervention group
Group type: EXPERIMENTAL
Intervention: Social inclusion condition
Number of subjects: 164
Study 30953874 — intervention group
Group type: EXPERIMENTAL
Intervention: Social rejection condition
Number of subjects: 164
Study 28586116 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota transplant (FMT) with 5 days of broad-spectrum antibiotic pretreatment and a single FMT enema from the same donor.
Number of subjects: 0
Study 28586116 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone.
Number of subjects: 0
Study 26715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 131
Study 26715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 131
Study 23279966 — intervention group
Group type: EXPERIMENTAL
Intervention: Student mentors
Number of subjects: 106
Study 23279966 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentors
Number of subjects: 106
Study 23279966 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentors working independently of researchers
Number of subjects: 106
Study 23279966 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 106
Study 21997429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 43
Study 21997429 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 43
Study 21997429 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 43
Study 18444793 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole plus 150 mg of fluconazole
Number of subjects: 310
Study 18444793 — intervention group
Group type: COMPARATOR
Intervention: metronidazole placebo plus fluconazole placebo
Number of subjects: 310
Study 16516541 — intervention group
Group type: EXPERIMENTAL
Intervention: Large electrode (36 x 36 mm)
Number of subjects: 14
Study 16516541 — intervention group
Group type: COMPARATOR
Intervention: Small electrode (6 x 6 mm)
Number of subjects: 14
Study 14979636 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (200 mg for children ≤ 7 years, 290 mg for children > 7 years)
Number of subjects: 89
Study 14979636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (260 mg glucose)
Number of subjects: 89
Study 10907966 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (30, 60, 120, or 240 microg/kg bolus)
Number of subjects: 82
Study 10907966 — intervention group
Group type: COMPARATOR
Intervention: Heparin (30, 60, 120, or 240 U/kg bolus)
Number of subjects: 82
Study 10907966 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (1.25, 2.5, 5, or 10 microg/kg/minute with or without a 250-microg/kg bolus)
Number of subjects: 82
Study 10907966 — intervention group
Group type: COMPARATOR
Intervention: Heparin (0.15, 0.20, 0.25, or 0.30 U/kg/minute with or without a 125-U/kg bolus)
Number of subjects: 82
Study 10907966 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (250-microg/kg bolus plus infusion of 15, 20, 30, and 40 microg/kg/minute)
Number of subjects: 82
Study 10907966 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 82
Study 10907966 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 82
Study 8698954 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 32
Study 8698954 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (opioid receptor blockade)
Number of subjects: 32
Study 1580283 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 10
Study 1580283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4005391 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg
Number of subjects: 21
Study 4005391 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 21
Study 4005391 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg
Number of subjects: 21
Study 4005391 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg (repeated dose)
Number of subjects: 21
Study 31087536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole with a loading dose of 25 mg/kg
Number of subjects: 166
Study 31087536 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole without specified loading dose
Number of subjects: 166
Study 30336850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg kg-1 then 4 mg kg-1 h-1)
Number of subjects: 40
Study 30336850 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 30336850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 40
Study 30336850 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine and saline
Number of subjects: 40
Study 27615041 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhalation breathing exercises using expirometer
Number of subjects: 63
Study 27615041 — intervention group
Group type: COMPARATOR
Intervention: Inhalation breathing exercises using incentive spirometry (Control)
Number of subjects: 63
Study 24979262 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coiling
Number of subjects: 17
Study 22309470 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management in combination with family engagement strategies (CM-FAM)
Number of subjects: 104
Study 22309470 — intervention group
Group type: COMPARATOR
Intervention: Usual services (US)
Number of subjects: 104
Study 20542492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 28
Study 20542492 — intervention group
Group type: COMPARATOR
Intervention: Laser Doppler Flowmetry (LDF)
Number of subjects: 28
Study 20542492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler Imaging (LDI)
Number of subjects: 28
Study 20542492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry (LDF) and Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 28
Study 18563775 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed dye laser (LPDL)
Number of subjects: 20
Study 15734833 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypocaloric very-low-fat diet (3%)
Number of subjects: 8
Study 12404080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) patches (21 mg/24 h)
Number of subjects: 24
Study 12404080 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 24
Study 12404080 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoking
Number of subjects: 24
Study 12404080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) patches
Number of subjects: 24
Study 9454908 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g/day for three days)
Number of subjects: 96
Study 9454908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9454908 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 96
Study 7897049 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizotypy assessed by the Perceptual Aberration Scale (PAS)
Number of subjects: 1646
Study 7897049 — intervention group
Group type: EXPERIMENTAL
Intervention: MAXCOV‐HITMAX taxometric analytic procedures
Number of subjects: 1646
Study 1710743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (Bezalip Mono) 400 mg once daily
Number of subjects: 36
Study 1710743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 39200 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated-breathing method
Number of subjects: 21
Study 39200 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated desensitization (placebo-control)
Number of subjects: 21
Study 29743827 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CMR) with a 6% unflavored maltodextrin solution
Number of subjects: 11
Study 29743827 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (PMR)
Number of subjects: 11
Study 29743827 — intervention group
Group type: COMPARATOR
Intervention: Drinking 'ad libitum' (DAL)
Number of subjects: 11
Study 26246020 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysoft patch (PP)
Number of subjects: 442
Study 26246020 — intervention group
Group type: COMPARATOR
Intervention: Modified Kugel patch (MK)
Number of subjects: 442
Study 24162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Inserter device (EndoSerter; Ocular Systems Inc, Winston‐Salem, NC)
Number of subjects: 20
Study 24162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheet glide (Surgical Glide; Beaver‐Visitec International Inc, Waltham, MA)
Number of subjects: 20
Study 24162751 — intervention group
Group type: COMPARATOR
Intervention: Control grafts
Number of subjects: 20
Study 24162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheet glide (cases 6-10)
Number of subjects: 20
Study 24162751 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoSerter (cases 6-10)
Number of subjects: 20
Study 22892729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-visit treatment
Number of subjects: 282
Study 22892729 — intervention group
Group type: COMPARATOR
Intervention: 2-visit treatment
Number of subjects: 282
Study 21061502 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective taking of a third party
Number of subjects: 114
Study 21061502 — intervention group
Group type: COMPARATOR
Intervention: Nonperspective taking
Number of subjects: 114
Study 17627003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral group
Number of subjects: 268
Study 17627003 — intervention group
Group type: COMPARATOR
Intervention: Population-based sampling group
Number of subjects: 268
Study 15842552 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin delivered via Pari LC + nebulizer
Number of subjects: 10
Study 15842552 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin delivered via MicroNeb III nebulizer
Number of subjects: 10
Study 15842552 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin delivered orally (80 mg)
Number of subjects: 10
Study 15842552 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin delivered intravenously (40 mg)
Number of subjects: 10
Study 15842552 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodynamic characteristics of nebulized doses from PARI
Number of subjects: 10
Study 15842552 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodynamic characteristics of nebulized doses from MN
Number of subjects: 10
Study 11932273 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A group (1.25 mg estrogen + 2.5 mg methyltestosterone/d)
Number of subjects: 40
Study 11932273 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A group
Number of subjects: 40
Study 11932273 — intervention group
Group type: COMPARATOR
Intervention: E group (1.25 mg/d)
Number of subjects: 40
Study 9577336 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (52% fat)
Number of subjects: 27
Study 9577336 — intervention group
Group type: COMPARATOR
Intervention: Balanced meal (24% fat)
Number of subjects: 27
Study 9577336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with reflux disease
Number of subjects: 27
Study 9577336 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 27
Study 8147328 — intervention group
Group type: EXPERIMENTAL
Intervention: 16:0-rich diet
Number of subjects: 17
Study 8147328 — intervention group
Group type: COMPARATOR
Intervention: 12:0 + 14:0-rich diet
Number of subjects: 17
Study 3276201 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of estradiol valerate topical gel
Number of subjects: 40
Study 3276201 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of prostaglandin E2 gel
Number of subjects: 40
Study 3276201 — intervention group
Group type: COMPARATOR
Intervention: Placebo prostaglandin E2 dosage
Number of subjects: 40
Study 28867130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 0.5 mg bevacizumab
Number of subjects: 21
Study 28867130 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser photoablation
Number of subjects: 21
Study 27912207 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERAs)
Number of subjects: 4894
Study 27912207 — intervention group
Group type: COMPARATOR
Intervention: Bosentan
Number of subjects: 4894
Study 27912207 — intervention group
Group type: COMPARATOR
Intervention: Macitentan
Number of subjects: 4894
Study 27912207 — intervention group
Group type: COMPARATOR
Intervention: Ambrisentan
Number of subjects: 4894
Study 26644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement‐based Treatment plus Women's Co‐Op (RBT + WC)
Number of subjects: 128
Study 26644132 — intervention group
Group type: COMPARATOR
Intervention: Case Management (CM)
Number of subjects: 128
Study 23162040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment of illness perceptions
Number of subjects: 156
Study 23162040 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 156
Study 21533643 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair (ASC) with double-row repair using resorbable anchors
Number of subjects: 34
Study 21533643 — intervention group
Group type: COMPARATOR
Intervention: Mini-open repair (MO) with transosseous repair
Number of subjects: 34
Study 21533643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASC and MO groups
Number of subjects: 34
Study 18542921 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume hemofiltration (HVHF 65 ml/(kg h))
Number of subjects: 20
Study 18542921 — intervention group
Group type: COMPARATOR
Intervention: Low volume hemofiltration (LVHF 35 ml/(kg h))
Number of subjects: 20
Study 16422722 — intervention group
Group type: EXPERIMENTAL
Intervention: Home support by nurse lactation consultants
Number of subjects: 138
Study 16422722 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 138
Study 12623632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sincere performance condition
Number of subjects: 0
Study 12623632 — intervention group
Group type: COMPARATOR
Intervention: Insincere performance condition
Number of subjects: 0
Study 12623632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability
Number of subjects: 0
Study 12623632 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 0
Study 11225967 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 19
Study 11225967 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 19
Study 9537146 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with a van Lint block
Number of subjects: 40
Study 9537146 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar block with a van Lint block
Number of subjects: 40
Study 8000269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of both leaflets
Number of subjects: 7
Study 8000269 — intervention group
Group type: COMPARATOR
Intervention: Standard mitral valve replacement
Number of subjects: 7
Study 3294407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium/clavulanate potassium
Number of subjects: 133
Study 3294407 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/gentamicin
Number of subjects: 133
Study 31045229 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 128
Study 31045229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 31045229 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid and Placebo
Number of subjects: 128
Study 28555011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat diet (20% energy), higher carbohydrate diet (65% energy)
Number of subjects: 242
Study 28555011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet (45% energy), higher fat diet (35% energy)
Number of subjects: 242
Study 28555011 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-rich diet (18% energy), higher fat diet (35% energy), lower carbohydrate diet (45% energy)
Number of subjects: 242
Study 28555011 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype
Number of subjects: 242
Study 28555011 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 242
Study 24646529 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-day educational intervention with lectures, structured feedback, and debriefing
Number of subjects: 29
Study 24646529 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 29
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants with tooth preparation
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealants with tooth preparation
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants without tooth preparation
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealants without tooth preparation
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealants
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth preparation
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants without preparation
Number of subjects: 25
Study 22353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries development
Number of subjects: 25
Study 20089776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (0, 5, 10, and 15 microg cholecalciferol/d)
Number of subjects: 419
Study 20089776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 18054638 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT plus IVTA
Number of subjects: 30
Study 18054638 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 30
Study 16076991 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy diet (1200 mg Ca/d, 3 servings of dairy)
Number of subjects: 63
Study 16076991 — intervention group
Group type: COMPARATOR
Intervention: Low dairy diet (500 mg/d, <1 serving/d)
Number of subjects: 63
Study 16076991 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy diet (1200 mg Ca/d, 3 servings of dairy) with caloric restriction (‐500 kcal/d)
Number of subjects: 63
Study 16076991 — intervention group
Group type: COMPARATOR
Intervention: Low dairy diet (500 mg/d, <1 serving/d) with caloric restriction (‐500 kcal/d)
Number of subjects: 63
Study 12242580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.27 mg
Number of subjects: 11
Study 12242580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10224181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant lavage with 15 mL/kg of diluted surfactant solution (Survanta) at a phospholipid concentration of 5 mg/mL administered in 2-mL aliquots
Number of subjects: 6
Study 10224181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant lavage
Number of subjects: 6
Study 10224181 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study 7925507 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 11472
Study 7925507 — intervention group
Group type: EXPERIMENTAL
Intervention: General population
Number of subjects: 11472
Study 7925507 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 11472
Study 7925507 — intervention group
Group type: COMPARATOR
Intervention: Diabetics
Number of subjects: 11472
Study 2573757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive monitoring (electronic fetal heart rate monitoring with scalp blood sampling when indicated)
Number of subjects: 13
Study 2573757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive monitoring
Number of subjects: 13
Study 2573757 — intervention group
Group type: COMPARATOR
Intervention: Control (intermittent intrapartum monitoring)
Number of subjects: 13
Study 2573757 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cases of cerebral palsy (both groups)
Number of subjects: 13
Study 1096831 — intervention group
Group type: EXPERIMENTAL
Intervention: Added lactose formula
Number of subjects: 29